



University of  
Zurich<sup>UZH</sup>

Zurich Open Repository and  
Archive

University of Zurich  
University Library  
Strickhofstrasse 39  
CH-8057 Zurich  
[www.zora.uzh.ch](http://www.zora.uzh.ch)

---

Year: 2018

---

## Probing the evolutionary robustness of two repurposed drugs targeting iron uptake in *Pseudomonas aeruginosa*

Rezzoagli, Chiara ; Wilson, David ; Weigert, Michael ; Wyder, Stefan ; Kümmerli, Rolf

**Abstract:** Background and objectives: Treatments that inhibit the expression or functioning of bacterial virulence factors hold great promise to be both effective and exert weaker selection for resistance than conventional antibiotics. However, the evolutionary robustness argument, based on the idea that antivirulence treatments disarm rather than kill pathogens, is controversial. Here, we probe the evolutionary robustness of two repurposed drugs, gallium and flucytosine, targeting the iron-scavenging pyoverdine of the opportunistic human pathogen *Pseudomonas aeruginosa*. Methodology: We subjected replicated cultures of bacteria to two concentrations of each drug for 20 consecutive days in human serum as an ex vivo infection model. We screened evolved populations and clones for resistance phenotypes, including the restoration of growth and pyoverdine production, and the evolution of iron uptake by-passing mechanisms. We whole-genome sequenced evolved clones to identify the genetic basis of resistance. Results: We found that mutants resistant against antivirulence treatments readily arose, but their selective spreading varied between treatments. Flucytosine resistance quickly spread in all populations due to disruptive mutations in *upp*, a gene encoding an enzyme required for flucytosine activation. Conversely, resistance against gallium arose only sporadically, and was based on mutations in transcriptional regulators, upregulating pyocyanin production, a redox-active molecule promoting siderophore-independent iron acquisition. The spread of gallium resistance was presumably hampered because pyocyanin-mediated iron delivery benefits resistant and susceptible cells alike. Conclusions and implications: Our work highlights that antivirulence treatments are not evolutionarily robust per se. Instead, evolutionary robustness is a relative measure, with specific treatments occupying different positions on a continuous scale.

DOI: <https://doi.org/10.1093/emph/eoy026>

Posted at the Zurich Open Repository and Archive, University of Zurich

ZORA URL: <https://doi.org/10.5167/uzh-161757>

Journal Article

Published Version



The following work is licensed under a Creative Commons: Attribution-NonCommercial 4.0 International (CC BY-NC 4.0) License.

Originally published at:

Rezzoagli, Chiara; Wilson, David; Weigert, Michael; Wyder, Stefan; Kümmerli, Rolf (2018). Probing the evolutionary robustness of two repurposed drugs targeting iron uptake in *Pseudomonas aeruginosa*. *Evolution, Medicine, and Public Health*, 6:246-259.

DOI: <https://doi.org/10.1093/emph/eoy026>



# Probing the evolutionary robustness of two repurposed drugs targeting iron uptake in *Pseudomonas aeruginosa*

Chiara Rezzoagli<sup>1</sup>\*, David Wilson, Michael Weigert, Stefan Wyder<sup>1</sup> and Rolf Kümmerli<sup>1</sup>\*

Department of Plant and Microbial Biology, University of Zurich, Zurich, Switzerland

\*Corresponding authors. Department of Plant and Microbial Biology, University of Zurich, Winterthurerstrasse 190, 8057 Zurich, Switzerland. Tel: +41-44-635-48-01; Fax: +41-44-634-82-04; E-mail: chiara.rezzoagli@uzh.ch (C.R.); rolf.kuemmerli@uzh.ch (R.K.)

Received 26 May 2018; revised version accepted 10 August 2018

## ABSTRACT

**Lay Summary:** We probed the evolutionary robustness of two antivirulence drugs, gallium and flucytosine, targeting the iron-scavenging pyoverdine in the opportunistic pathogen *Pseudomonas aeruginosa*. Using an experimental evolution approach in human serum, we showed that antivirulence treatments are not evolutionarily robust per se, but vary in their propensity to select for resistance.

**Background and objectives:** Treatments that inhibit the expression or functioning of bacterial virulence factors hold great promise to be both effective and exert weaker selection for resistance than conventional antibiotics. However, the evolutionary robustness argument, based on the idea that antivirulence treatments disarm rather than kill pathogens, is controversial. Here, we probe the evolutionary robustness of two repurposed drugs, gallium and flucytosine, targeting the iron-scavenging pyoverdine of the opportunistic human pathogen *Pseudomonas aeruginosa*.

**Methodology:** We subjected replicated cultures of bacteria to two concentrations of each drug for 20 consecutive days in human serum as an *ex vivo* infection model. We screened evolved populations and clones for resistance phenotypes, including the restoration of growth and pyoverdine production, and the evolution of iron uptake bypassing mechanisms. We whole-genome sequenced evolved clones to identify the genetic basis of resistance.

**Results:** We found that mutants resistant against antivirulence treatments readily arose, but their selective spreading varied between treatments. Flucytosine resistance quickly spread in all populations due to disruptive mutations in *upp*, a gene encoding an enzyme required for flucytosine activation. Conversely, resistance against gallium arose only sporadically, and was based on mutations in transcriptional regulators, upregulating pyocyanin production, a redox-active molecule promoting siderophore-independent iron acquisition. The spread of gallium resistance was presumably hampered because pyocyanin-mediated iron delivery benefits resistant and susceptible cells alike.

**Conclusions and implications:** Our work highlights that antivirulence treatments are not evolutionarily robust *per se*. Instead, evolutionary robustness is a relative measure, with specific treatments occupying different positions on a continuous scale.

**KEYWORDS:** antivirulence therapy; experimental evolution; *Pseudomonas aeruginosa*; gallium; flucytosine; drug resistance

## INTRODUCTION

There is currently much interest in therapeutic approaches that inhibit the expression or functioning of bacterial virulence factors [1–8]. Virulence factors are structures and molecules that allow bacteria to establish and maintain infections [9, 10]. Examples of virulence factors include flagella and pili to adhere to the host tissue, secreted enzymes, tissue-damaging toxins and siderophores to scavenge iron from the host [11]. Approaches that target these traits are called antivirulence treatments. There is great hope that disarming rather than killing pathogens is an efficient and evolutionarily robust way to manage infections [2, 12–15]. In particular, it is assumed that antivirulence treatments exert weaker selection for resistance than conventional antibiotics because pathogens are not killed directly. However, empirical evidence for the evolutionary robustness of antivirulence treatments is controversial with positive and negative reports currently balancing each other out [16–21].

The controversy entails both conceptual and practical aspects. On the conceptual level, some define antivirulence approaches as treatments that specifically target virulence factors without affecting pathogen growth [2, 22], while others argue that it is unlikely that virulence factors do not affect pathogen fitness, and thus simply use the mechanistic part of the definition [5, 15]. On the practical level, there are debates about what exactly a resistance phenotype is [15], as it could include restoration of virulence factor production, growth (if affected), and/or the activation of a bypassing mechanism, restoring the virulence phenotype [19]. Moreover, there is a shortage of studies examining resistance evolution under realistic conditions in replicated populations, both at the phenotypic and genetic level.

Here, we tackle these issues by examining the mechanistic and evolutionary potential of resistance evolution against two repurposed drugs, gallium and flucytosine, which both target the iron-scavenging pyoverdine of the opportunistic human pathogen *Pseudomonas aeruginosa* [19, 23, 24]. Pyoverdine is an important virulence factor during acute infections [19, 25–31]. It is required to obtain iron from host proteins, such as transferrin and lactoferrin [32]. Given its importance, it has been proposed that drugs interfering with iron uptake could be effective therapeutics to control infections [33]. Gallium and flucytosine both fulfill this role, albeit through different modes of action. Gallium, a repurposed cancer drug, is an iron-mimic and binds irreversibly to secreted pyoverdine, thereby rendering the molecules useless

for iron uptake [19, 23, 31]. Flucytosine, a repurposed antifungal drug, enters the bacterium, where it is enzymatically activated to a fluorinated ribonucleotide. This active form inhibits, via a yet unknown mechanism, the expression of the *pvdS* iron starvation sigma factor controlling pyoverdine synthesis [24, 34].

In a first set of experiments, we examined whether these two drugs affect the growth of *P. aeruginosa* in human blood serum, a medium that has recently been established as an *ex vivo* infection model [35]. We hypothesize that gallium and flucytosine are likely to reduce pathogen fitness as they induce iron starvation [19, 23, 36, 37]. In addition, antivirulence drugs, like any other drugs, might have deleterious off-target effects affecting growth. Gallium at high dosage, for instance, can penetrate into bacterial cells, where it interferes with redox-active enzymes [38, 39]. Flucytosine, once activated, is known to affect RNA synthesis, which might negatively affect growth [40].

In a second experiment, we examined whether mutants, resistant against these two repurposed drugs, evolve and spread through bacterial populations. To this end, we exposed replicated populations of *P. aeruginosa* to two different concentrations of gallium and flucytosine in human serum. Together with a drug-free control treatment, we let the treated populations evolve for 20 consecutive days in 8-fold replication, by transferring a fraction of the evolving cultures to fresh human serum on a daily basis. Following experimental evolution, we screened evolved populations and clones for possible resistance phenotypes, including the restoration of growth, restoration of virulence factor production and the evolution of a bypassing mechanism for iron uptake [15, 19]. Finally, we sequenced the whole genome of evolved clones to uncover the genetic basis of potential resistance mechanisms.

Resistance evolution requires two processes: the supply of mutations conferring resistance and appropriate selection regimes favoring the spread of these mutants [41]. With regard to mutation supply, some common resistance mechanisms (e.g. drug degradation, prevention of drug influx and increased drug efflux) are less likely to apply for gallium, which is an ion and acts outside the cell [19]. Therefore, with fewer possible routes to resistance being available, we predict gallium to show higher evolutionarily robustness than flucytosine. However, as for the spread of mutants, both drugs could be evolutionarily robust because they target a secreted virulence factor, which can be shared as a public good between pathogen individuals (iron-loaded pyoverdine can be taken up by all bacteria with a matching receptor) [42, 43]. Consequently, if resistance entails the resumption of virulence factor production then

resistant mutants should not spread because they bear the cost of resumed virulence factor production, whilst sharing the benefit with everyone else in the population, including the drug-susceptible individuals [12, 14, 16, 20]. Conversely, if these drugs have deleterious off-target effects, we predict the evolutionary robustness to decline, and accelerated spread of resistance under drug exposure, as for traditional antibiotics.

## METHODOLOGY

### Strains and culturing conditions

We used the genetically well-characterized *P. aeruginosa* PAO1 wildtype strain for all experiments. For some assays, we further used a set of knockout mutants in the PAO1 background as control strains (see [Supplementary Table S1](#)). Overnight cultures were grown in 8 ml Lysogeny broth (LB) in 50-ml Falcon tubes, incubated at 37°C, 200 rpm for 18 h. For all experiments, we washed overnight cultures with 0.8% NaCl solution and adjusted them to OD<sub>600</sub> = 2.5. Bacteria were further diluted to a final starting of OD<sub>600</sub> = 2.5 × 10<sup>-3</sup>. All experiments were carried out in human serum, supplemented with HEPES (50 mM) to buffer the medium at physiological pH. Moreover, to impose a standardized iron limitation across experiments, we added the iron chelator human apo-transferrin (100 µg/ml), which is typically present in blood serum at high concentration, and its co-factor NaHCO<sub>3</sub> (20 mM). We used gallium (GaNO<sub>3</sub>) and flucytosine (5-fluorocytosine) as antibacterials. All chemicals, including human serum, were purchased from Sigma-Aldrich, Switzerland.

### Growth and virulence factor inhibition curves

To assess the extent to which gallium and flucytosine inhibit PAO1 growth and pyoverdine production, we subjected bacterial cultures to a seven-step antibacterial concentration gradient: 0–512 µM for GaNO<sub>3</sub> and 0–140 µg/ml for flucytosine. Overnight cultures of bacteria were grown and diluted as described above and inoculated into 200 µl of human serum on 96-well plates. Plates were incubated at 37°C in a Tecan Infinite M-200 plate reader (Tecan Group Ltd., Switzerland). We tracked growth by measuring OD at 600 nm and pyoverdine-associated natural fluorescence (excitation: 400 nm, emission: 460 nm) every 15 min for 24 h. Plates were shaken for 15 s (3 mm orbital displacement) prior to each reading event.

### Experimental evolution

We exposed wildtype cultures of PAO1 to experimental evolution for 20 days under five different selective regimes in 8-fold replication. The five regimes included a no-drug control, and a low and a high concentration treatment for both drugs (gallium: 50 and


280 µM; flucytosine: 10 and 140 µg/ml). The antibacterial concentrations were inferred from the dose–response curves ([Fig. 1](#)). To initiate experimental evolution, an overnight culture of PAO1 was grown as described above, and individual wells on a 96-well plate were inoculated with 10 µl of culture (diluted to a final density of 10<sup>6</sup> cells per well) in 190 µl iron-limited human serum. Incubation occurred in the plate reader at 37°C for 23.5 h, and OD<sub>600</sub> was measured every 15 min prior to a brief shaking event. Subsequently, cultures were diluted in 0.8% NaCl and transferred to a new plate containing fresh media. We adjusted the dilution factor proportional to the overall growth per treatment; no-drug control: 2 × 10<sup>-3</sup> (days 1–10) and 4 × 10<sup>-3</sup> (days 11–20); antibacterial treatments: 10<sup>-3</sup> (days 1–10) and 2 × 10<sup>-3</sup> (days 11–20). Following transfers, we added 100 µl of a 50% glycerol–LB solution to cultures for storage at –80°C.

### Quantification of resistance profiles

To test whether populations evolved under antibacterial exposure restored growth and/or pyoverdine production, we exposed evolved lineages to the drug concentrations they experienced during experimental evolution in 5-fold replication. Following a standard protocol with incubation at 37°C, shaking at 160 rpm, for 24 h [44], we compared the OD<sub>600</sub> and pyoverdine-associated fluorescence of evolved lineages relative to the ancestor wildtype grown under drug and no-drug treatment.

To assess potential resistance profiles of individual clones, we streaked out aliquots of evolved lineages onto LB plates. After overnight incubation at 37°C, we randomly picked 200 clones (5 colonies per lineage), and assessed their growth and pyoverdine production in 3-fold replication, as described above. Moreover, we performed an in-depth analysis for 20 (four per treatment) randomly picked single clones by quantifying their drug–inhibition curve, following the protocol described above.

To test whether bacteria upregulated alternative iron-acquisition mechanisms, we quantified pyocyanin and protease production of selected clones. For pyocyanin production, overnight bacterial cultures were inoculated into 1 ml of LB (starting OD<sub>600</sub> = 10<sup>-6</sup>), and incubated at 37°C for 24 h, shaken at 160 rpm. We measured pyocyanin in the cell-free supernatant through absorbance at 691 nm [19]. For protease production, overnight bacterial cultures were inoculated in human serum (starting OD<sub>600</sub> = 2.5 × 10<sup>-3</sup>), and incubated at 37°C for 24 h, shaken at 160 rpm. Subsequently, we centrifuged cultures at 3700 rpm for 15 min to obtain protease-containing supernatants. To measure proteolytic activity, we adapted the protocol by [45]: 0.1 ml azocasein solution (30 mg/ml) were mixed with 0.3 ml 50 mM phosphate buffer (pH 7.5), and 0.1 ml culture supernatant. During incubation at 37°C (2 h), proteases hydrolyze azocasein and release the azo-dye. Proteolytic reaction was stopped by adding 0.5 ml 20% trichloroacetic acid, samples centrifuged at 12 000 rpm (10 min), and



**Figure 1.** Gallium and flucytosine affect both growth and pyoverdine production of *P. aeruginosa* in human serum (HS). Both antivirulence drugs reduce growth of bacterial cultures in a dose-dependent manner (A, B), albeit following different patterns: gallium curbs bacterial growth only at relatively high concentrations (A), whereas flucytosine already reduces growth at low concentrations (B). Both drugs further affect pyoverdine production (C, D). When increasing gallium exposure, bacteria first upregulate pyoverdine production at intermediate drug concentrations, but then down-scale investment levels at high drug concentrations (C). In contrast, flucytosine administration leads to an almost complete abolishment of pyoverdine production even at the lowest drug concentration. All data are expressed as average of growth yield, scaled relative to the drug-free treatment. Error bars denote standard errors of the mean across 6 (for flucytosine) and 18 (for gallium) replicates. Dose-response curves were fitted using a spline fit. Vertical lines indicate the drug concentrations used in the experimental evolution

proteolytic activity measured through absorbance of the azo-dye at 366 nm.

### Sequencing analysis

We further isolated the genomic DNA of the selected 16 clones evolved under drug regimes and sequenced their genomes. We used the GenElute Bacterial Genomic DNA kit (Sigma Aldrich) for DNA isolation. DNA concentrations were assayed using the Quantifluor dsDNA sample kit (Promega). Samples were sent to the Functional Genomics Center Zurich for library preparation (Nextera XT) and sequencing. Sequencing was performed on the Illumina HiSeq 4000 platform with single-end 125 base pair reads. Adapter sequences were clipped using Trimmomatic v0.33 [46] and reads trimmed using Flexbar v2.5 [47]. We aligned the reads to the PAO1 reference genome using BWA v0.7.12 [48]. We applied GATK v3.5 [49] indel realignment, duplicate removal and HaplotypeCaller SNP/INDEL discovery according to the GATK Best Practices recommendations. This generated a variant call format (VCF) file, from which the following variants were

discarded: (i) coverage <20 reads; (ii) Fisher Strand score >30.0, ensuring that there is no strand bias in the data; (iii) QD value <2.0 (confidence value that there is a true variation at a given site); and (iv) clustered variants ( $\geq 3$  variants in 35 nt window) as they likely present sequencing or alignment artifacts. This filtering process yielded a list of potential SNPs and small INDELs, which we annotated using snpEff 4.1g [50] and then screened manually, compared with the sequenced genome of our ancestor wildtype for relevant mutations in gene coding and intergenic regions (Supplementary Table S2).

### Statistical analysis

We used RStudio for statistical analysis (version 0.99.896, with R version 3.3.0). We analyzed growth curves and pyoverdine production profiles using the *grofit* package [51]. We fitted nonparametric model (Splines) curves to estimate growth yield and integral (area under the curve). For all analyses, we scaled growth yield and pyoverdine production relative to the untreated ancestral wildtype. We used general linear mixed effect models to



compare whether growth parameters or pyoverdine profiles differ in evolved cultures treated with or without antibacterials. To test for differences between evolved lines and the ancestral wildtype, we used Welch's two-sample *t*-test. To compare the dose-response curve of evolved clones, we first fitted spline curves to the inhibition curves, then estimated the integrals of these fits, and compared the scaled fits relative to the ancestor wildtype using analysis of variance (ANOVA). Protease and pyocyanin production of evolved clones and the ancestor wildtype were corrected for cell number (OD<sub>600</sub>) and analyzed using ANOVA.

## RESULTS

### Gallium and flucytosine curb growth and pyoverdine production in human serum

To confirm that human serum is an iron-limited media, in which pyoverdine is important for growth, we compared the growth of our wildtype strain PAO1 with the pyoverdine-negative mutant PAO1  $\Delta pvdD$  in either pure human serum or human serum supplemented with transferrin (Supplementary Fig. S1). As expected for iron-limited media, we observed significantly reduced growth of the siderophore-deficient mutants compared with the wildtype (ANOVA:  $t_{49} = -8.13$ ,  $P < 0.0001$ ) under both conditions.

We then subjected PAO1 to a range of drug concentrations in human serum supplemented with transferrin. The resulting dose-response curves revealed that both drugs significantly affected growth and pyoverdine production, albeit following different patterns (Fig. 1). For gallium, growth reduction was moderate at low concentrations, and only became substantial at high concentrations ( $\text{GaNO}_3 \geq 256 \mu\text{M}$ , Fig. 1A). Gallium treatment affected pyoverdine synthesis in a complex way (Fig. 1C), yet consistent with previous findings [19]: at intermediate gallium concentrations, pyoverdine is up-regulated to compensate for the gallium-induced pyoverdine inhibition, and down-regulated at higher concentrations, when pyoverdine-mediated signaling becomes impaired [23]. For flucytosine, already the lowest concentration caused a substantial growth reduction (Fig. 1B) and completely stalled pyoverdine production, with the reduction remaining fairly constant across the concentration gradient (Fig. 1D). We obtained similar response profiles when growing PAO1 in human serum without added transferrin (Supplementary Fig. S2), indicating that transferrin supplementation does not affect the drugs' mode of actions. For all subsequent experiments, we used human serum with added transferrin to ensure strong iron limitation and to standardize conditions across experiments.

### Do bacteria evolve population-level resistance to antivirulence treatments?

We subjected PAO1 wildtype cultures to experimental evolution both in the absence and presence of gallium and flucytosine (two


concentrations each). Eight independent lines per treatment were daily transferred to fresh human serum for a period of 20 days. Subsequently, we assessed whether evolved populations improved growth and/or pyoverdine production levels compared with the treated ancestral wildtype, which could provide first hints of resistance evolution.

For growth (Fig. 2A), we found that evolved lines grew significantly better under drug exposure than the ancestral wildtype (Welch's *t*-tests, gallium low ( $50 \mu\text{M}$ ):  $t_{11,9} = -4.96$ ,  $P = 0.0003$ ; gallium high ( $280 \mu\text{M}$ ):  $t_{13,3} = -6.48$ ,  $P < 0.0001$ ; flucytosine low ( $10 \mu\text{g/ml}$ ):  $t_{12,2} = -5.09$ ,  $P = 0.0002$ ; flucytosine high ( $140 \mu\text{g/ml}$ ):  $t_{7,5} = -11.79$ ,  $P < 0.0001$ ). Because growth increase could simply reflect adaptation to media components other than drugs, we also analyzed changes in growth performance of the lines evolved without drugs. It turned out that some of the untreated evolved lineages also showed improved growth compared with the ancestral wildtype, but the overall increase across lines was not significant ( $t_{9,1} = -1.61$ ,  $P = 0.1424$ , Fig. 2A).

For pyoverdine production, we observed no significant change for the lines evolved under low gallium concentration (comparison relative to the treated ancestor, Welch's *t*-test:  $t_{8,8} = 0.94$ ,  $P = 0.3719$ ) (Fig. 2B). Conversely, lines evolved under the other three drug regimes all showed significantly increased pyoverdine production (Fig. 2B) (gallium high:  $t_{13,1} = -3.69$ ,  $P = 0.0026$ ; flucytosine low:  $t_{7,2} = -7.64$ ,  $P = 0.0001$ ; flucytosine high:  $t_{9,6} = -54.65$ ,  $P < 0.0001$ ). While the increase was moderate for the gallium high treatment, there was full restoration of pyoverdine production in both flucytosine treatments (no significant difference relative to the ancestral untreated wildtype, ANOVA, flucytosine low:  $t_{8,8} = -1.31$ ,  $P = 0.1944$ ; flucytosine high:  $t_{8,8} = 0.42$ ,  $P = 0.6766$ ). Although pyoverdine restoration might be taken as evidence for resistance evolution, analysis of the control lines shows that a significant increase in pyoverdine production also occurred in the absence of drugs (Welch's *t*-test,  $t_{9,1} = -4.03$ ,  $P = 0.0047$ , Fig. 2B).

### Screening for resistance profiles in evolved single clones

While the population analyses above show that drug resistance and general media adaptation could both contribute to the evolved population growth and pyoverdine phenotypes, we decided to screen individual clones for in-depth analysis. In a first step, we isolated 200 random clones (i.e. 40 per treatment), and individually analyzed their growth and pyoverdine production. These analyses revealed high between-clone variation in growth and pyoverdine production (Supplementary Figs S3 and S4), suggesting that most evolved populations were heterogeneous, consisting of multiple different genotypes. Interestingly, we observed that 25% of the evolved clones from the no-drug control lines lost the ability to produce pyoverdine (Supplementary Fig. S4). This observation matches the results from previous studies, showing that iron-limitation selects for nonproducers that cheat on the



**Figure 2.** Population level growth and pyoverdine production after evolution in human serum. PAO1 cultures were exposed to either no treatment, low (50  $\mu$ M) or high (280  $\mu$ M) gallium, low (10  $\mu$ g/ml) or high (140  $\mu$ g/ml) flucytosine concentrations during a 20-day experimental evolution experiment in 8-fold replication. Following evolution, we assessed growth and pyoverdine production of evolved populations (displayed on the x-axis) and compared their performance relative with the untreated (gray solid line, set to 1) and treated ancestral wildtype (black dashed line). (A) Compared with the treated ancestral wildtype, growth of evolved populations significantly increased under all treatment regimes. Growth also increased in some but not all of the nontreatment lines. (B) Pyoverdine production of evolved populations significantly increased relative to the untreated ancestral wildtype under all conditions, also in the no treatment lines. This indicates that increased pyoverdine production might be a general response to growth in human serum, which makes it difficult to disentangle resistance evolution from media adaptation. Error bars show the standard error of the mean across five independent replicates

pyoverdine produced by others [52, 53]. Increased pyoverdine production at the population level (Fig. 2B) is then typically the result of wildtype cells over-compensating for the presence of nonproducers [54, 55]. Conversely, we did not detect nonproducers in the four drug treatments, which suggest that selection pressures differ between the nondrug and the drug treatments.


In a second step, we randomly picked 16 single clones (4 per drug treatment) and tested whether these evolved clones differ in their drug dose response curve relative to the ancestral wildtype. We observed that three out of eight clones subjected to gallium (Fig. 3A–D) and all eight clones subjected to flucytosine showed a significantly altered dose response (Fig. 3E–H). Clones GL\_2 and GL\_3, evolved under low gallium, showed a significant increase in pyoverdine production under intermediate gallium concentrations (between 8 and 128  $\mu$ M), which goes along with an improved growth performance for GL\_2, but not GL\_3. In contrast, clone GH\_1, evolved under high gallium concentration, did not show an altered pyoverdine production response, but grew significantly better when exposed to gallium (Fig. 3A–D). For the eight clones evolved under the flucytosine regime, changes in the dose-response curves were both striking and uniform: growth and pyoverdine production were no longer affected by the drug

(Fig. 3E–H). Since these dose-response curves directly include a control for media adaptation (i.e. the no-drug treatment), our results indicate that all eight clones evolved complete resistance to flucytosine. For gallium, on the other hand, our data suggest that three out of the eight clones exhibited a phenotype that is compatible with at least partial resistance. To check whether these putative resistance profiles are unique to clones evolved under drug treatment, we further assessed the dose-response curves of four clones from the no-drug control lines (Supplementary Fig. S5). All these clones responded to both drugs in the same way as the susceptible ancestral wildtype, confirming that adaptation to human serum does not *per se* result in resistant phenotypes.

### Linking phenotypes to genotypes

Our whole-genome sequencing of the 16 focal clones revealed a small number of SNPs and INDELs, which have emerged during experimental evolution (Table 1). All the clones evolved under flucytosine treatment had acquired mutations in the coding sequence of *upp*. There were 4 different types of mutations, including two different nonsynonymous SNPs, a 15-bp deletion





**Figure 3.** Changes in dose–response curves for evolved single clones indicate resistance evolution. 16 randomly picked clones, four per treatment, were exposed to a range of drug concentrations to test whether their dose–response altered during evolution compared with the ancestral wildtype (black circles and lines). (A, B) Growth dose–response curves under gallium treatment show that two evolved clones (GL\_2 and GH\_1) are significantly less inhibited than the ancestral wildtype. (C, D) Pyoverdine dose–response curves under gallium treatment show that two evolved clones (GL\_2 and GL\_3) make significantly more pyoverdine than the ancestral wildtype. (E, F) Growth dose–response curves under flucytosine treatment show that all evolved clones grow significantly better than the ancestral wildtype, and are in fact no longer affected by the drug. (G, H) Pyoverdine dose–response curves under flucytosine treatment show that all evolved clones produce significantly more pyoverdine than the ancestral wildtype, and are in fact no longer affected by the drug. Growth and pyoverdine production were measured after 24 h. For each clone, values are scaled relative to its performance in human serum without drugs (absolute values of pyoverdine and growth in the absence of treatment are reported in Supplementary Fig. S6). We used spline functions to fit dose–response curves, and used the integral (area under the curve) to quantify the overall dose response of each clone across the concentration gradient. Error bars denote standard errors of the mean across six replicates. Asterisks represent significance levels: \* $P < 0.05$ ; \*\*\* $P < 0.0001$ , based on linear model with  $df=45$

and a 1-bp insertion (Supplementary Table S3). The *upp* gene encodes for a uracil phosphoribosyl-transferase, an enzyme required for the intra-cellular activation of flucytosine [56, 57].

For the clones evolved under gallium treatment, the mutational pattern was more heterogeneous (Table 1). No mutations were detected for three clones (GH\_2, GH\_3, GH\_4). In contrast, the three clones with significantly altered dose responses had

mutations potentially explaining their phenotypes: clone GH\_1 featured a 3-nt deletion in *mvaU*, whereas the clones GL\_2 and GL\_3 were mutated in *vfr*. Both genes encode transcriptional regulators involved in the regulation of virulence factors, including proteases, pyocyanin and pyoverdine.


In addition, several clones had mutations in *dipA* (dispersion-induced phosphodiesterase A; GL\_1, GL\_4, FH\_4) and *morA*

**Table 1.** List of mutations in evolved single clones

Treatment	Clone	Gene <sup>a</sup>	Description	Mutation	Type	Position <sup>b</sup>
Gallium Low	GL_1	<i>dipA</i>	Dispersion-induced phosphodiesterase A	CA → C	INDEL	5642855–5642856
	GL_2	<i>vfr</i>	Transcriptional regulator	C → T	SNP	706108
	GL_3	<i>vfr</i>	Transcriptional regulator	C → T	SNP	706108
		<i>PA3801</i>	Conserved hypothetical protein	A → G	SNP	4260811
		<i>morA</i>	Motility regulator	G → T	SNP	5158144
Gallium High	GL_4	<i>dipA</i>	Dispersion-induced phosphodiesterase A	CA → C	INDEL	5642855–5642856
	GH_1	<i>mvaU</i>	Transcriptional regulator	GAGC → G	INDEL	3016276–3016279
	GH_2	None				
	GH_3	None				
	GH_4	None				
Flucytosine Low	FL_1	<i>upp</i>	Uracil phosphoribosyltransferase	T → C	SNP	5213244
		<i>yfiR</i>	Tripartite signaling complex	C → T	SNP	1214975
		<i>PA1369</i>	Hypothetical protein	C → T	SNP	1483680
		<i>PA2770-PA2771</i>	Intergenic region	G → A	SNP	3129202
	FL_2	<i>upp</i>	Uracil phosphoribosyltransferase	GAGAAGATCT CCGGGA → G	INDEL	5213011–5213037
	FL_3	<i>upp</i>	Uracil phosphoribosyltransferase	A → C	SNP	5212855
		<i>upp</i>	Uracil phosphoribosyltransferase	A → G	SNP	5213146
	FL_4	<i>upp</i>	Uracil phosphoribosyltransferase	T → C	SNP	5213244
		<i>groEL</i>	Protein chaperone	G → A	SNP	4916838
		<i>PA2770-PA2771</i>	Intergenic region	G → A	SNP	3129202
	FH_1	<i>upp</i>	Uracil phosphoribosyltransferase	G → GC	INDEL	5212852
		<i>upp</i>	Uracil phosphoribosyltransferase	A → C	SNP	5212855
		<i>fliF</i>	Flagella M-ring outer membrane protein precursor	CA → C	INDEL	1194060–1194061
	FH_2	<i>upp</i>	Uracil phosphoribosyltransferase	A → C	SNP	5212855
		<i>morA</i>	Motility regulator	G → A	SNP	5159713
Flucytosine High	FH_3	<i>upp</i>	Uracil phosphoribosyltransferase	A → C	SNP	5212855
		<i>fliF</i>	Flagella M-ring outer membrane protein precursor	TCGTCC → T	INDEL	1193365–1193370
	FH_4	<i>upp</i>	Uracil phosphoribosyltransferase	A → C	SNP	5212855
		<i>dipA</i>	Dispersion-induced phosphodiesterase A	GA → G	INDEL	5643059–5643060

<sup>a</sup>Only mutations not found in the ancestor wildtype PAO1 are reported. Common mutations among all samples and the ancestor are listed in Supplementary Table S2.

<sup>b</sup>Position on PAO1 reference genome.



**Figure 4.** Upregulation of pyocyanin or protease production as potential bypassing mechanisms for iron acquisition under gallium treatment. The eight sequenced clones evolved under gallium treatments (low: 50  $\mu$ M, high: 280  $\mu$ M) were screened for their change in the secretion of pyocyanin (A) and proteases (B) relative to the ancestral wildtype. Standard protocols were used for the phenotypic screens in drug free media (see Methodology for details). All values are corrected for cell number, and scaled relative to the ancestor wildtype (black line). We included the strains PAO1  $\Delta rhIR$  (deficient for pyocyanin production) and PAO1  $\Delta lasR$  (deficient for protease production) as negative controls in the respective assays (dashed lines). Error bars denote standard errors of the mean across three (for proteases) and eight (for pyocyanin) replicates. Asterisks represent significance levels: \* $P < 0.05$ ; \*\*\* $P < 0.0001$ , based on ANOVA.

(motility regulator; GL\_3, FH\_2). The repeated yet unspecific appearance of these mutations could suggest that they represent nondrug-specific adaptations to human serum. Altogether, our sequencing analysis identified three potential targets explaining resistance evolution: the gene *upp* for flucytosine, and the genes encoding the transcriptional regulators *vfr* and *mvaU* for gallium.

### Evolution of bypassing mechanisms for iron acquisition under gallium treatment


It was proposed that bypassing mechanisms, which guarantee iron uptake in a siderophore-independent manner, could confer resistance to gallium [19]. One such by-passing mechanism could involve the up-regulation of pyocyanin, a molecule that can reduce ferric to ferrous iron outside the cell, thereby promoting direct iron uptake [18, 58]. This scenario indeed seems to apply to the three clones mutated in *mvaU* or *vfr*, two regulators that control directly (*mvaU*) or indirectly (*vfr*) the expression of pyocyanin [59, 60]. These clones displayed significantly increased pyocyanin production compared with the ancestral wildtype (Fig. 4A; ANOVA, GH\_1:  $t_{79} = 9.64$ ,  $P < 0.0001$ ; GL\_2:  $t_{99} = 6.13$ ,  $P < 0.0001$ ; GL\_3:  $t_{99} = 14.8$ ,  $P < 0.0001$ ).

A second by-passing mechanism could operate via increased protease production, which would allow iron acquisition from transferrin or heme through protease-induced hydrolysis [29, 61]. We found no support for this hypothesis. In fact, six of the

evolved clones exhibited reduced and not increased protease activity (Fig. 4B). Moreover, the two clones with significantly increased protease activity (ANOVA, GL\_1:  $t_{10} = 13.22$ ,  $P < 0.0001$ ; GL\_4:  $t_{10} = 11.60$ ,  $P < 0.0001$ , Fig. 4B) did not show an altered drug dose–response curve.

### Inactivation of Upp is responsible for resistance to flucytosine

Next, we tested whether the mutations in *upp* are responsible for flucytosine resistance. The enzyme Upp (uracil phosphoribosyl-transferase) is essential for the activation of flucytosine within the cell. The natural function of Upp is to convert uracil to the nucleotide precursor UMP in the salvage pathway of pyrimidine (Fig. 5A). However, *P. aeruginosa* can also produce UMP through the conversion of L-glutamine and L-aspartate [62] (Fig. 5A), suggesting that *upp* is not essential for pyrimidine metabolism. Mutations in this gene could thus prevent flucytosine activation, and confer drug resistance. To test this hypothesis, we compared the flucytosine dose–response curve of the wildtype strain with an isogenic (transposon) mutant (MPAO1 $\Delta upp$ ). Consistent with the patterns of the evolved clones (Fig. 3G), we found that MPAO1 $\Delta upp$  was completely insensitive to flucytosine, with neither growth (Fig. 5B) nor pyoverdine production (Fig. 5C) being affected by the drug. These results indicate that *upp* inactivation is a simple and efficient mechanism to become flucytosine resistant.



**Figure 5.** Upp is a nonessential enzyme, and mutations in its gene result in flucytosine resistance. **(A)** Flucytosine interferes with the pyrimidine metabolism in *P. aeruginosa*. The drug enters the cell through the transporter CodB (not shown), where it is first converted to fluorouracil by the cytosine deaminase CodA, and then to fluoro-UMP by the uracil phosphoribosyl-transferase Upp. Fluoro-UMP is a modified nucleotide precursor, the action of which results in RNA molecules with compromised functionality. Through an as yet unknown mechanism, fluoro-UMP also arrests pyoverdine synthesis in *P. aeruginosa*. Importantly, the nucleotide-precursor UMP can also be produced through an alternative *de-novo* pathway from the amino acids L-glutamine and L-aspartate, making Upp a nonessential enzyme in this bacterium. Experiments with the transposon mutant MPAO1  $\Delta upp$  (deficient for Upp production) indeed demonstrate that the lack of Upp no longer affects strain growth **(B)** and pyoverdine production **(C)**. This demonstrates that the inactivation of *upp* is a simple and efficient way to evolve resistance to flucytosine. Experiments were carried out in human serum across a range of flucytosine concentrations. Growth and pyoverdine production of MPAO1  $\Delta upp$  (gray-dashed lines) and its corresponding wildtype MPAO1 (black-solid lines) were measured after 24 h for each treatment separately in 6-fold replication. All values are scaled relative to the drug-free treatment. For statistical analysis, we compared the integrals of the dose–response curves between the mutant and the wildtype strain (Welch’s *t*-test, growth:  $t_{4,3} = -5.56$ ,  $P = 0.0041$ ; pyoverdine production:  $t_{5,0} = -48.80$ ,  $P < 0.0001$ )

## DISCUSSION

New treatment approaches against the multi-drug resistant ESKAPE pathogens, to which *P. aeruginosa* belongs, are desperately needed [8, 63, 64]. In this context, treatments that disarm rather than kill bacteria have attracted particular interest, because such approaches have been proposed to be both effective in managing infections and sustainable in the sense that resistance should not easily evolve [2, 5, 12–15]. Promising approaches include the quenching of toxins [65, 66], siderophores required for iron-scavenging [19, 23, 24, 37, 67], and quorum sensing molecules regulating virulence factor production [3]. In our study, we probed the evolutionary robustness argument by focusing on two repurposed drugs (gallium and flucytosine) targeting siderophore production of *P. aeruginosa*. Using a combination of replicated experimental evolution and phenotypic and genotypic analysis, we show that the often-recited argument of antivirulence

drugs being evolutionarily robust is not supported. Instead, we provide a nuanced view on the molecular mechanisms and selective forces that can lead to resistance. For flucytosine, for instance, we found repeated resistance evolution based on a mechanism that prevents drug activation inside the cell, which mitigates possible pleiotropic and deleterious effects caused by this drug. For gallium, meanwhile, two types of partially resistant mutants, based on siderophore bypassing mechanisms, arose. However, these mutants only sporadically emerged, indicating that their potential to selectively spread in populations is compromised. Our work highlights that evolutionary robustness is a relative measure with specific treatments lying on different positions on a continuum. Thus, our task is not to argue about whether antivirulence drugs are evolutionarily robust or not, but to assess the relative position of each novel treatment on this continuum.



**Table 2.** Estimation of mutation supply during experimental evolution

Treatment	Population bottleneck (CFU)	Number of cell divisions <sup>a</sup>	Expected mutations <sup>b</sup> in any nucleotide	Expected mutations <sup>b</sup> in <i>mvaU</i> <sup>c</sup>	Expected mutations <sup>b</sup> in <i>vfr</i> <sup>c</sup>	Expected mutations <sup>b</sup> in <i>upp</i> <sup>c</sup>
No drug	2.1×10 <sup>5</sup>	8.4×10 <sup>10</sup>	83.9	3.0×10 <sup>4</sup>	5.4×10 <sup>4</sup>	5.4×10 <sup>4</sup>
Gallium low	1.9×10 <sup>5</sup>	3.5×10 <sup>10</sup>	34.8	1.2×10 <sup>4</sup>	2.2×10 <sup>4</sup>	2.2×10 <sup>4</sup>
Gallium high	4.8×10 <sup>4</sup>	8.7×10 <sup>9</sup>	8.7	3.0×10 <sup>3</sup>	5.6×10 <sup>3</sup>	5.6×10 <sup>3</sup>
Flucytosine low	9.8×10 <sup>4</sup>	1.8×10 <sup>10</sup>	17.4	6.2×10 <sup>3</sup>	1.1×10 <sup>4</sup>	1.1×10 <sup>4</sup>
Flucytosine high	4.8×10 <sup>4</sup>	8.7×10 <sup>9</sup>	8.7	3.1×10 <sup>3</sup>	5.6×10 <sup>3</sup>	5.6×10 <sup>3</sup>

<sup>a</sup>Across all 8 replicated population and 20 transfers.  
<sup>b</sup>Assuming a mutation rate of  $\sim 10^{-9}$  per nucleotide per cell division for *P. aeruginosa* PAO1 [79].  
<sup>c</sup>Considering only the length of the coding sequence (354 bp for *mvaU*, 645 bp for *vfr*, 639 bp for *upp*).

Our findings indicate that it is difficult to define antivirulence treatments based on fitness effects [2, 6, 8, 22]. This is because fitness effects might vary in response to the ecological context of the media or the infection. For instance, prior work [24] showed that flucytosine does not affect bacterial growth in trypticase soy broth dialysate, whereas we found significant fitness effects in human serum. Endorsing the fitness-based definition would mean that flucytosine could only be considered as an antivirulence drug in very specific cases, i.e. in one media but not in another. This might cause confusion when we aim to bring these new treatment approaches to the clinic. While we agree that it would be ideal to find compounds that only curb virulence but not fitness, it seems that such cases are rare and context-dependent [5, 15]. For all those reasons, we support the more general definition of antivirulence treatments as advocated in previous reviews [5, 15]: drugs intended to target bacterial virulence factors.

Important to note is that even when we use the more general definition of antivirulence the chances are good that many of the new treatment approaches are evolutionary more robust than classical antibiotics. This is nicely illustrated in the case of gallium, where we found that partially resistant mutants only sporadically occurred. Given the mutation rate in *P. aeruginosa* and the number of generations that occurred in our experiment, the frequency of such mutants should be much higher if they had experienced a clear selective advantage (Table 2). Our data thus highlight that it is important to distinguish between the appearance of resistant mutants and their evolutionary potential to spread through populations.

At the mechanistic level, we isolated mutants with increased pyocyanin production, a potential mechanism to by-pass gallium-mediated pyoverdine quenching. Pyocyanin is a redox active molecule that can extracellularly reduce ferric to ferrous iron [18, 58]. The upregulation of pyocyanin was associated with mutations in *mvaU*, encoding a positive regulator of pyocyanin production, and *vfr*, encoding a global virulence factor regulator [10]. Mutations in *Vfr* can activate PQS (*Pseudomonas* Quinolone Signal) synthesis,

which is known to promote pyocyanin and pyoverdine synthesis [60, 68]. At the evolutionary level, however, the selective advantage of these mutations seemed to be compromised because they occurred only in some of the sequenced clones (Table 1). One plausible explanation for their sporadic appearance is that pyocyanin could serve as a public good, reducing iron outside the cell, thereby generating benefits for other individuals in the vicinity, including the drug-susceptible wildtype cells. This scenario would support the argument that antivirulence strategies should target collective traits, because this would prevent resistant mutants to fix in populations [12, 14, 16, 19, 20]. The relative success of these mutants is then determined by the viscosity of the environment, determining the shareability of secreted compounds [69], and the potential for negative-frequency dependent selection, where strain frequency settles at an intermediate ratio [70–72].

The pattern clearly differed for flucytosine, where we found pervasive resistance evolution. Although it is not exactly known how flucytosine inhibits pyoverdine synthesis, we argue that resistance evolution could mainly be caused by negative effects on other traits than pyoverdine synthesis. Flucytosine undergoes several enzymatic modifications within the cell, finally resulting in fluorinated ribonucleotides. While flucytosine was shown to inhibit pyoverdine synthesis [24], it likely also interferes with nucleotide synthesis, which might compromise RNA functionality more generally [73]. This sets the stage for selection to favor mutants with alleviated fitness costs under drug exposure. Our results suggest that cells achieved this through mutations in *upp*. The scheme depicted in Fig. 5A shows that the essential pyrimidine nucleotide precursor UMP can be synthesized either through the salvage pathways reutilizing exogenous free bases and nucleosides, or via a *de novo* biosynthesis pathway using L-glutamine or L-aspartate. While the salvage pathway is typically preferred because it requires less energy, it generates the harmful fluoro-UMP under flucytosine treatment. Thus, the abolishment of the salvage pathway through mutations in *upp* and the switching to the *de novo* biosynthesis pathway provides a selective advantage under flucytosine exposure. The notion that off-target effects might

compromise the evolutionary robustness of antivirulence drugs, is also supported by the work of Maeda *et al.* [17]. They showed that resistance to the quorum-quenching compound C-30 (brominated furanone) evolves repeatedly via upregulation of a drug efflux pump. The spread of these mutants in their experiment can be explained by the fact that quorum quenching did not only inhibit virulence factor production, but also compromised the ability of cells to grow in adenosine medium, which requires a functional quorum sensing system [74].

## CONCLUSIONS AND IMPLICATIONS

Our work advances research on antivirulence drugs on multiple fronts. First, it shows that resistant phenotypes are difficult to define, as they can involve the restoration of growth, the resumption of virulence factor production, and/or the activation of a bypassing mechanism. Detailed phenotypic and genotypic analyses, as those proposed in our study, are required to disentangle background adaptation from resistance evolution. Second, we show that antivirulence approaches are neither completely evolution-proof nor does the notion ‘all roads lead to resistance’ apply [75]. A detailed evolutionary analysis for each individual drug is required to assess its position on the continuum between the two extremes. Third, we advocate the application of more rigorous evolutionary approaches to quantify resistance evolution. While there are rigorous standards to describe the precise molecular mode of action of a novel antibacterial [21, 76], there is much room for improvement for standards regarding the quantification and characterization of resistance evolution [77, 78].

## ACKNOWLEDGEMENTS

We thank Adin Ross-Gillespie for advice, the Functional Genomics Center Zurich for technical support with the strain sequencing.

## SUPPLEMENTARY DATA

Supplementary data is available at EMPH online.

## FUNDING

This work was funded by the Swiss National Science Foundation (R.K.) with grant no. PP00P3\_165835 and by the University of Zurich as part of the university research priority program: Evolution in Action.

**Conflict of interest:** None declared.

## DATA ACCESSIBILITY

Data available on Figshare repository, under DOI 10.6084/m9.figshare.7058909.

## REFERENCES

1. Escaich S. Antivirulence as a new antibacterial approach for chemotherapy. *Curr Opin Chem Biol* 2008; **12**:400–8.
2. Rasko DA, Sperandio V. Anti-virulence strategies to combat bacteria-mediated disease. *Nat Rev Drug Discov* 2010; **9**:117–28.
3. LaSarre B, Federle MJ. Exploiting quorum sensing to confuse bacterial pathogens. *Microbiol Mol Biol Rev* 2013; **77**:73–111.
4. Maura D, Ballok AE, Rahme LG. Considerations and caveats in anti-virulence drug development. *Curr Opin Microbiol* 2016; **33**:41–6.
5. Vale PF, McNally L, Doeschl-Wilson A. Beyond killing. *Evol Med Public Heal* 2016; **2016**:148–57.
6. Johnson BK, Abramovitch RB. Small molecules that sabotage bacterial virulence. *Trends Pharmacol Sci* 2017; **38**:339–62.
7. Rampioni G, Visca P, Leoni L *et al.* Drug repurposing for antivirulence therapy against opportunistic bacterial pathogens. *Emerg Top Life Sci* 2017; **1**:13.
8. Dickey SW, Cheung GYC, Otto M. Different drugs for bad bugs: antivirulence strategies in the age of antibiotic resistance. *Nat Rev Drug Discov* 2017; **16**:457–15.
9. Rahme LG, Stevens EJ, Wolford SF *et al.* Common virulence factors for bacterial pathogenicity in plants and animals. *Science* 1995; **268**:1899–902.
10. Balasubramanian D, Schnepfer L, Kumari H *et al.* A dynamic and intricate regulatory network determines *Pseudomonas aeruginosa* virulence. *Nucleic Acids Res* 2013; **41**:1–20.
11. Wu HJ, Wang AHJ, Jennings MP. Discovery of virulence factors of pathogenic bacteria. *Curr Opin Chem Biol* 2008; **12**:93–101.
12. André J-B, Godelle B. Multicellular organization in bacteria as a target for drug therapy. *Ecol Lett* 2005; **8**:800–10.
13. Baron C. Antivirulence drugs to target bacterial secretion systems. *Curr Opin Microbiol* 2010; **13**:100–5.
14. Pepper JW. Drugs that target pathogen public goods are robust against evolved drug resistance. *Evol Appl* 2012; **5**:757–61.
15. Allen RC, Popat R, Diggle SP, Brown SP. Targeting virulence: can we make evolution-proof drugs? *Nat Rev Microbiol* 2014; **12**:300–8.
16. Mellbye B, Schuster M. The sociomicrobiology of antivirulence drug resistance: a proof of concept. *MBio* 2011; **2**:e0013111.
17. Maeda T, García-Contreras R, Pu M *et al.* Quorum quenching quandary: resistance to antivirulence compounds. *ISME J* 2012; **6**:493–501.
18. García-Contreras R, Lira-Silva E, Jasso-Chávez R *et al.* Isolation and characterization of gallium resistant *Pseudomonas aeruginosa* mutants. *Int J Med Microbiol* 2013; **303**:574–82.
19. Ross-Gillespie A, Weigert M, Brown SP *et al.* Gallium-mediated siderophore quenching as an evolutionarily robust antibacterial treatment. *Evol Med Public Heal* 2014; **2014**: 18–29.
20. Gerdt JP, Blackwell HE. Competition studies confirm two major barriers that can preclude the spread of resistance to quorum-sensing inhibitors in bacteria. *ACS Chem Biol* 2014; **9**:2291–9.
21. Sully EK, Malachowa N, Elmore BO *et al.* Selective chemical inhibition of *agr* quorum sensing in *Staphylococcus aureus* promotes host defense with minimal impact on resistance. *PLoS Pathog* 2014; **10**:e1004174.
22. Clatworthy AE, Pierson E, Hung DT. Targeting virulence: a new paradigm for antimicrobial therapy. *Nat Chem Biol* 2007; **3**:541–8.
23. Kaneko Y, Thoendel M, Olakanmi O *et al.* The transition metal gallium disrupts *Pseudomonas aeruginosa* iron metabolism and has antimicrobial and antibiofilm activity. *J Clin Invest* 2007; **117**:877–88.



24. Imperi F, Massai F, Facchini M *et al.* Repurposing the antimycotic drug flucytosine for suppression of *Pseudomonas aeruginosa* pathogenicity. *Proc Natl Acad Sci U S A* 2013; **110**:7458–63.
25. Meyer JM, Neely A, Stintzi A *et al.* Pyoverdine is essential for virulence of *Pseudomonas aeruginosa*. *Infect Immun* 1996; **64**:518–23.
26. Takase H, Nitanai H, Hoshino K *et al.* Impact of siderophore production on *Pseudomonas aeruginosa* infections in immunosuppressed mice. *Infect Immun* 2000; **68**:1834–9.
27. Harrison F, Browning LE, Vos M *et al.* Cooperation and virulence in acute *Pseudomonas aeruginosa* infections. *BMC Biol* 2006; **4**:21.
28. Cornelis P, Dingemans J. *Pseudomonas aeruginosa* adapts its iron uptake strategies in function of the type of infections. *Front Cell Infect Microbiol* 2013; **3**:1–7.
29. Bonchi C, Imperi F, Minandri F *et al.* Repurposing of gallium-based drugs for antibacterial therapy. *BioFactors* 2014; **40**:303–12.
30. Granato ET, Harrison F, Kümmerli R *et al.* Do bacterial “virulence factors” always increase virulence? A meta-analysis of pyoverdine production in *Pseudomonas aeruginosa* as a test case. *Front Microbiol* 2016; **7**:1–13.
31. Weigert M, Ross-Gillespie A, Leinweber A *et al.* Manipulating virulence factor availability can have complex consequences for infections. *Evol Appl* 2017; **10**:91–101.
32. Valenti P, Berlutti F, Conte MP *et al.* Lactoferrin functions: current status and perspectives. *J Clin Gastroenterol* 2004; **38**:S127–9.
33. Smith DJ, Lamont IL, Anderson GJ *et al.* Targeting iron uptake to control *Pseudomonas aeruginosa* infections in cystic fibrosis. *Eur Respir J* 2013; **42**:1723–36.
34. Visca P, Imperi F, Lamont IL. Pyoverdine siderophores: from biogenesis to biosignificance. *Trends Microbiol* 2007; **15**:22–30.
35. Bonchi C, Frangipani E, Imperi F *et al.* Pyoverdine and proteases affect the response of *Pseudomonas aeruginosa* to gallium in human serum. *Antimicrob Agents Chemother* 2015; **59**:5641–6.
36. Banin E, Lozinski A, Brady KM *et al.* The potential of desferrioxamine-gallium as an anti-*Pseudomonas* therapeutic agent. *Proc Natl Acad Sci U S A* 2008; **105**:16761–6.
37. DeLeon K, Balldin F, Watters C *et al.* Gallium maltolate treatment eradicates *Pseudomonas aeruginosa* infection in thermally injured mice. *Antimicrob Agents Chemother* 2009; **53**:1331–7.
38. Chitambar CR. Gallium-containing anticancer compounds. *Future Med Chem* 2012; **4**:1257–72.
39. Hijazi S, Visca P, Frangipani E. Gallium-protoporphyrin IX inhibits *Pseudomonas aeruginosa* growth by targeting cytochromes. *Front Cell Infect Microbiol* 2017; **7**:1–15.
40. Waldorf AR, Polak A. Mechanisms of action of 5-fluorocytosine. *Antimicrob Agents Chemother* 1983; **23**:79–85.
41. Hughes D, Andersson DI. Evolutionary trajectories to antibiotic resistance. *Annu Rev Microbiol* 2017; **71**:579–96.
42. Griffin AS, West SA, Buckling A. Cooperation and competition in pathogenic bacteria. *Nature* 2004; **430**:1024–7.
43. Inglis RF, Biernaskie JM, Gardner A *et al.* Presence of a loner strain maintains cooperation and diversity in well-mixed bacterial communities. *Proc R Soc B Biol Sci* 2016; **283**:20152682.
44. Kümmerli R, Jiricny N, Clarke LS *et al.* Phenotypic plasticity of a cooperative behaviour in bacteria. *J Evol Biol* 2009; **22**:589–98.
45. Chessa JP, Petrescu I, Bentahir M *et al.* Purification, physico-chemical characterization and sequence of a heat labile alkaline metalloprotease isolated from a psychrophilic *Pseudomonas* species. *Biochim Biophys Acta - Protein Struct Mol Enzymol* 2000; **1479**:265–74.
46. Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina sequence data. *Bioinformatics* 2014; **30**:2114–20.
47. Dodt M, Roehr J, Ahmed R *et al.* FLEXBAR—flexible barcode and adapter processing for next-generation sequencing platforms. *Biology (Basel)* 2012; **1**:895–905.
48. Li H, Durbin R. Fast and accurate short read alignment with Burrows–Wheeler transform. *Bioinformatics* 2009; **25**:1754–60.
49. McKenna A, Hanna M, Banks E *et al.* The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. *Genome Res* 2010; **20**:1297–303.
50. Cingolani P, Platts A, Wang LL *et al.* A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff. *Fly (Austin)* 2012; **6**:80–92.
51. Kahm M, Hasenbrink G, Lichtenberg-Fraté H *et al.* grofit: fitting biological growth curves with R. *J Stat Softw* 2010; **33**:1–21.
52. Harrison F, Paul J, Massey RC *et al.* Interspecific competition and siderophore-mediated cooperation in *Pseudomonas aeruginosa*. *ISME J* 2008; **2**:49–55.
53. Dumas Z, Kümmerli R. Cost of cooperation rules selection for cheats in bacterial metapopulations. *J Evol Biol* 2012; **25**:473–84.
54. Harrison F. Dynamic social behaviour in a bacterium: *Pseudomonas aeruginosa* partially compensates for siderophore loss to cheats. *J Evol Biol* 2013; **26**:1370–8.
55. Ross-Gillespie A, Dumas Z, Kümmerli R. Evolutionary dynamics of interlinked public goods traits: an experimental study of siderophore production in *Pseudomonas aeruginosa*. *J Evol Biol* 2015; **28**:29–39.
56. Beck DA, O'Donovan GA. Pathways of pyrimidine salvage in *Pseudomonas* and former *Pseudomonas*: detection of recycling enzymes using high-performance liquid chromatography. *Curr Microbiol* 2008; **56**:162–7.
57. Edlind TD, Katiyar SK. Mutational analysis of flucytosine resistance in *Candida glabrata*. *Antimicrob Agents Chemother* 2010; **54**:4733–8.
58. Cox CD. Role of pyocyanin in the acquisition of iron from transferrin. *Infect Immun* 1986; **52**:263–70.
59. Li C, Wally H, Miller SJ *et al.* The multifaceted proteins MvaT and MvaU, members of the H-NS family, control arginine metabolism, pyocyanin synthesis, and prophage activation in *Pseudomonas aeruginosa* PAO1. *J Bacteriol* 2009; **191**:6211–8.
60. Diggle SP, Matthijs S, Wright VJ *et al.* The *Pseudomonas aeruginosa* 4-quinolone signal molecules HHQ and PQS play multifunctional roles in quorum sensing and iron entrapment. *Chem Biol* 2007; **14**:87–96.
61. Döring G, Pfestorf M, Botzenhart K *et al.* Impact of Proteases on Iron Uptake of *Pseudomonas aeruginosa* Pyoverdine from Transferrin and Lactoferrin. *Infect Immun* 1988; **56**:291–3.
62. Isaac JH, Holloway BW. Control of pyrimidine biosynthesis in *Pseudomonas aeruginosa*. *J Bacteriol* 1968; **96**:1732–41.
63. Pendleton JN, Gorman SP, Gilmore BF. Clinical relevance of the ESKAPE pathogens. *Expert Rev anti Infect Ther* 2013; **11**:297–308.
64. Brown D. Antibiotic resistance breakers: can repurposed drugs fill the antibiotic discovery void? *Nat Rev Drug Discov* 2015; **14**:821–32.
65. Lu C, Maurer CK, Kirsch B *et al.* Overcoming the unexpected functional inversion of a PqsR antagonist in *Pseudomonas aeruginosa*: an in vivo potent antivirulence agent targeting pqs quorum sensing. *Angew Chemie Int Ed* 2014; **53**:1109–12.

66. Henry BD, Neill DR, Becker KA *et al.* Engineered liposomes sequester bacterial exotoxins and protect from severe invasive infections in mice. *Nat Biotechnol* 2015; **33**:81–8.
67. Kelson AB, Carnevali M, Truong-Le V. Gallium-based anti-infectives: targeting microbial iron-uptake mechanisms. *Curr Opin Pharmacol* 2013; **13**:707–16.
68. Lin J, Zhang W, Cheng J *et al.* A *Pseudomonas* T6SS effector recruits PQS-containing outer membrane vesicles for iron acquisition. *Nat Commun* 2017; **8**:14888.
69. Weigert M, Kümmerli R. The physical boundaries of public goods cooperation between surface-attached bacterial cells. *Proc. R. Soc. B* 2017; **284**: 20170631.
70. Ross-Gillespie A, Gardner A, West SA *et al.* Frequency dependence and cooperation: theory and a test with bacteria. *Am Nat* 2007; **170**:331–42.
71. Raymond B, West SA, Griffin AS *et al.* The dynamics of cooperative bacterial virulence in the field. *Science* 2012; **337**:85–8.
72. Yurtsev EA, Chao HX, Datta MS *et al.* Bacterial cheating drives the population dynamics of cooperative antibiotic resistance plasmids. *Mol Syst Biol* 2013; **9**:683.
73. Harbers E, Chaudhuri NK, Heidelberger C. Studies on fluorinated pyrimidines. VIII. Further biochemical and metabolic investigations. *J Biol Chem* 1959; **234**:1255–62.
74. Dandekar AA, Chugani S, Greenberg EP. Bacterial quorum sensing and metabolic incentives to cooperate. *Science* 2012; **338**:264–6.
75. Breidenstein EBM, de la Fuente-Núñez C, Hancock REW. *Pseudomonas aeruginosa*: all roads lead to resistance. *Trends Microbiol* 2011; **19**:419–26.
76. Ling LL, Schneider T, Peoples AJ *et al.* A new antibiotic kills pathogens without detectable resistance. *Nature* 2015; **517**:455–9.
77. Perron GG, Zasloff M, Bell G. Experimental evolution of resistance to an antimicrobial peptide. *Proc R Soc B Biol Sci* 2006; **273**:251–6.
78. Hochberg ME, Jansen G. Bacteria: assessing resistance to new antibiotics. *Nature* 2015; **519**:158.
79. McElroy KE, Hui JGK, Woo JKK *et al.* Strain-specific parallel evolution drives short-term diversification during *Pseudomonas aeruginosa* biofilm formation. *Proc Natl Acad Sci* 2014; **111**:E1419–27.